Cardiac Tumors

Cardiac tumors are rare enough that they’re often the subject of case reports rather than case series, which means the real diagnostic skill here is pattern recognition built from precise, memorized distribution data rather than broad experience. See Approach to Cardiac Masses for the foundational framework — confirming a true mass, and distinguishing it from a normal variant or artifact — that this page builds directly on.

Classification and Overall Frequency

Cardiac tumors are classified as primary (arising from the heart itself) or secondary/metastatic (spreading to the heart from elsewhere), and as benign or malignant — and the relative frequency of these categories runs counter to intuition. Metastatic disease is found in 10% to 25% of cancer patients at autopsy, making it genuinely far more common than primary cardiac disease, even though primary tumors receive disproportionate clinical attention precisely because of their rarity. About 75% of primary cardiac tumors are benign — but a pathologically benign tumor can still produce “malignant” hemodynamic consequences if it obstructs normal blood flow, which is exactly why the echocardiographic exam always assesses both the anatomic extent of a tumor and its physiologic consequences, not just whether it’s present.

How Well Echo Actually Detects These Tumors

In one series of 149 patients, 2D transthoracic echocardiography detected a pathologically confirmed cardiac tumor with 93.3% sensitivity, down to a minimum detectable size of 0.5–1.0 cm²; 2D TEE raised sensitivity to 96.8% in the same series. 3D echocardiography adds genuine incremental value — it provided additional preoperative information in 37% of patients studied, and is estimated to meaningfully contribute in roughly 18% of all intracardiac masses. 2D imaging also tends to underestimate true mass diameter: by as much as 24.6% for 2D TTE and 19.8% for 2D TEE, compared with real-time 3D measurement — a genuinely important limitation, since mass diameter carries real prognostic and embolic-risk implications regardless of whether the mass is a vegetation, thrombus, or tumor.

Primary Benign Tumors

Tumor	Approximate frequency
Myxoma	27%
Pericardial cyst	18%
Lipoma	10%
Papillary fibroelastoma	10%
Hemangioma	3%
Bronchogenic cyst	2%
Mesothelioma of the AV node	1%

Myxoma

The single most common primary cardiac tumor in adults. Myxomas classically arise from the fossa ovalis region of the interatrial septum via a pedicle, with a genuinely precise distribution worth knowing exactly: roughly 75% arise in the left atrium, 18% in the right atrium, and 4% each in the LV and RV, with more than one simultaneous site of origin in about 5% of cases.

Clinical presentation is a classic triad, though any single element can dominate: constitutional symptoms (fever, malaise), obstructive symptoms (heart failure or syncope from obstruction to ventricular filling — large left atrial myxomas can prolapse across the mitral annulus in diastole, producing the “tumor plop” heard on auscultation), and embolic events, thought to arise from the tumor’s friable surface or adherent thrombus.

Echocardiographic appearance is often genuinely heterogeneous — irregular “frond” or “grape cluster” morphology, nonhomogeneous echogenicity sometimes with calcification, and visible variation even between individual myxomas: some have a smooth surface, while others are villous and friable, and the villous, friable morphology is specifically associated with a higher risk of fragmentation and embolism.

A genuinely difficult differential: a sessile myxoma in an atypical atrial location can be hard to distinguish from thrombus. The clinical context tips the balance — atrial arrhythmia, a recent ablation procedure, or mitral stenosis all favor thrombus over myxoma in this specific, ambiguous scenario.

A standard four-view protocol — parasternal long-axis, parasternal short-axis at the mitral valve level, apical four-chamber, and subcostal — has been shown to provide highly accurate information for surgical planning in most cases. TEE becomes genuinely necessary when a very large myxoma nearly fills the LA chamber with broad intimal contact throughout the cardiac cycle, since the attachment stalk itself may not be clearly seen on TTE in this scenario — and all four pulmonary veins and both venae cavae should be specifically checked for local tumor extension in this situation.

Four explicit goals define the echo exam once a myxoma is suspected: identify the precise site of attachment; confirm the valve leaflets themselves are not involved; exclude additional, separate masses; and — after surgery — document complete excision. The functional degree of obstruction to ventricular filling is assessed qualitatively with color flow imaging and quantitatively with the pressure half-time method, the same technique used for native mitral stenosis.

Recurrence occurs in 2–5% of cases, either at the original site (suggesting incomplete resection) or from an additional, previously undiscovered focus — which is exactly why thorough intraoperative TEE and long-term surveillance matter, particularly in familial myxoma syndromes or cases with multiple lesions.

Papillary Fibroelastoma

The second most common benign primary tumor overall, and the most common tumor of valvular origin — in one autopsy series, representing about 10% of all cardiac tumors found. Usually small (most are under 1 cm) and attached by a short, discrete stalk.

Location follows a specific, worth-memorizing pattern: the aortic valve is affected in 44% of cases, followed by the mitral valve in 35%, the tricuspid valve in 15%, and the pulmonic valve in 8% — less commonly, fibroelastomas occur on non-valvular endocardium.

Its frond-like surface gives it a distinctive “shimmering” appearance on echocardiography. Because of its small size, TEE is genuinely superior to TTE for detection. 3D cropping and manipulation can help identify a discrete stalk when it isn’t clearly apparent on 2D imaging — and identifying that stalk is itself a key diagnostic clue, since it’s what separates a fibroelastoma from other entities in its differential:

• From a vegetation: see Approach to Cardiac Masses for the full attachment-side logic — a fibroelastoma characteristically attaches to the downstream side of the valve, the opposite side from a typical vegetation.
• From Libman-Sacks endocarditis (the sterile valvulopathy seen in systemic lupus erythematosus): a fibroelastoma is stalk-attached with independent motion, while a Libman-Sacks lesion is sessile and located along the leaflet coaptation point itself.
• From a Lambl excrescence, which shares a similar histologic appearance but a different morphology: Lambl excrescences are wispy and fibrolinear, while a fibroelastoma is round and well-formed.

Small fibroelastomas are usually of no clinical consequence; the embolic significance of larger ones remains somewhat controversial, though embolic events are more common specifically when the tumor is mobile and stalk-attached, and superimposed thrombus formation with resulting systemic embolization has been described.

Other Benign Tumors

• Lipoma and lipomatous hypertrophy of the interatrial septum — the latter is a genuine mass mimic covered in detail on the Approach to Cardiac Masses page, characterized by sparing of the fossa ovalis.
• Rhabdomyoma and fibroma — the most common benign tumors specifically in children, typically located in the ventricular myocardium (unlike the atrial-predominant myxoma). Despite benign histology, both can cause conduction abnormalities, arrhythmias, and even sudden death. Fibromas tend to be larger and more often symptomatic, appearing hyperreflective on echo and often speckled with calcium; rhabdomyomas are typically small and can be solitary or multiple.
• Hemangioma — a highly vascular tumor, distinguished functionally by visible perfusion on contrast echocardiography.
• Pericardial and bronchogenic cysts — genuinely common findings (pericardial cysts alone account for about 18% of all primary cardiac masses in some series), though structurally distinct from true myocardial or endocardial tumors.

Primary Malignant Tumors

Cardiac sarcomas are the most common primary cardiac malignancy, occurring in order of frequency as angiosarcoma, rhabdomyosarcoma, fibrosarcoma, and leiomyosarcoma. They share a genuine predilection for the right atrium, tend to be large, and appear as broad-based lobular masses — though polypoid or intramyocardial growth, with extension into the inferior vena cava, also occurs. Calcification can be seen specifically with osteosarcoma.

These are aggressive tumors that spread rapidly from an intramural origin into the cardiac chambers, the pericardium, or both, typically presenting with obstructive symptoms from impaired right heart filling, pericardial effusion or tamponade, arrhythmia, or embolization. Metastases are frequently already present at the time of diagnosis. Median survival is only 6 to 12 months, even with the combination of chemotherapy, radiotherapy, and surgical resection that optimal management calls for — resection itself is often not feasible given tumor size and intramyocardial location.

The Sarcoma-Versus-Lymphoma Distinction: Genuinely Decision-Changing

Primary cardiac lymphoma shares sarcoma’s predilection for the right heart, particularly the right atrium, and can look morphologically similar on imaging — which makes distinguishing the two clinically urgent rather than academic, since their prognosis and treatment diverge sharply. Metastatic lymphoma to the heart is far more common than primary cardiac lymphoma, but when primary disease does occur, it’s most often of the diffuse large B-cell variety. A pericardial effusion commonly accompanies it. Surprisingly, the constitutional symptoms typical of lymphoma elsewhere are often absent — patients more often present with precordial pain or dyspnea instead. In genuine contrast to sarcoma’s grim prognosis, primary cardiac lymphoma can respond favorably to surgery, anthracycline-based chemotherapy, or both — particularly when detected early. This is exactly why obtaining a definitive pathologic diagnosis, rather than presuming sarcoma from imaging appearance and right atrial location alone, genuinely changes what a patient is told about their prognosis.

Metastatic Tumors

Metastatic cardiac involvement spreads through several distinct mechanisms — direct invasion from the mediastinum, hematogenous spread, lymphatic spread, and direct venous extension into the heart — and the route of spread is often tied to the specific primary tumor type:

• Right heart metastases commonly arrive via direct extension through the inferior vena cava — seen with renal cell carcinoma, leiomyosarcoma, and certain gynecologic malignancies specifically.
• Left heart involvement can occur via the pulmonary veins, a route specifically associated with lung cancer extension.
• Hematologic malignancies can also involve the heart, particularly the pericardium or myocardium — lymphoma can produce actual tumor foci with clinical manifestations, while leukemic infiltration tends to be subtler on imaging despite being reported as the more common of the two.

Nearly three-quarters of all cardiac metastases originate from lung, breast, or hematologic malignancies. Melanoma has the single highest rate of pericardial metastasis of any tumor type — though because melanoma itself is comparatively uncommon, a cardiac metastatic tumor is still statistically more likely to represent one of the more prevalent malignancies above. Lymphomas associated with AIDS show frequent and extensive cardiac involvement, worth remembering in the right clinical context.

About three-quarters of metastatic cardiac disease involves the pericardium and epicardium specifically, manifesting as a pericardial effusion with or without tamponade physiology. Because echocardiography rarely identifies the actual cause of a pericardial effusion directly, a new or worsening effusion in a patient with known malignancy should itself prompt consideration of cardiac metastatic involvement, rather than being attributed reflexively to a benign cause. Regardless of the primary malignancy, cardiac metastatic involvement is generally a marker of widely disseminated disease, and treatment is typically palliative.

The Echo Exam for a Suspected Malignant Tumor

Three elements structure the assessment once a malignant primary or metastatic tumor is suspected:

1. Anatomic location and extent of tumor involvement.
2. Physiologic consequences — valvular regurgitation, chamber obliteration, or outflow obstruction.
3. Associated findings — particularly a pericardial effusion, and whether tamponade physiology is present.

Because metastatic disease is far more likely than a primary cardiac malignancy, a thorough search for a potential primary site is always warranted when a malignant-appearing cardiac mass is found — and ultimately, the diagnosis depends on tissue examination, not imaging appearance alone.

Where Advanced Imaging Adds Real Value

Echocardiography remains the key first-line modality for detecting a mass and generating an initial differential, given its ability to characterize location, size, attachment site, and hemodynamic significance directly. CMR’s specific advantage is tissue characterization and perfusion assessment — genuinely useful for distinguishing tumor from thrombus, which echo’s appearance alone often cannot settle definitively.

In a ten-year retrospective review of CMR performed specifically to further characterize cardiac masses already found on echocardiography, CMR identified a mass in 82% of cases, categorizing findings as tumor (76%), thrombus (20%), or inconclusive (4%). CMR’s diagnostic accuracy was 97% for tumor and 94% for thrombus — a genuinely high level of discrimination, driven largely by perfusion: a lack of post-contrast enhancement is a useful determinant of thrombus specifically, since thrombus is avascular while most tumors show some degree of vascularity and perfusion. CT has a more limited, complementary role, mainly useful for assessing a mass’s relationship to extracardiac mediastinal structures that fall outside echocardiography’s field of view.

How to Approach a Suspected Cardiac Tumor: A Practical Sequence

1. Confirm a true mass is present using the framework on the Approach to Cardiac Masses page before proceeding further.
2. Note the precise location and attachment pattern — chamber of origin, valvular versus non-valvular, pedunculated versus sessile — since location alone narrows the differential substantially given how consistently these tumor types cluster by site.
3. Assess physiologic consequences directly — functional obstruction (qualitatively by color flow, quantitatively by pressure half-time when relevant), associated regurgitation, and chamber size.
4. Weigh the clinical context actively — age (pediatric versus adult favors different tumor types entirely), a known malignancy elsewhere, recent arrhythmia or ablation, and systemic symptoms all shift the differential.
5. Use TEE when the tumor is small, posteriorly located, or when the attachment stalk isn’t clearly seen on TTE — genuinely decision-relevant for both myxoma and fibroelastoma specifically.
6. Recommend CMR when tumor-versus-thrombus remains genuinely ambiguous, given its substantially higher diagnostic accuracy for this specific distinction via perfusion assessment.
7. Never presume a specific malignant diagnosis from imaging location alone — a right atrial mass could be sarcoma or lymphoma, with genuinely different prognoses, and only tissue examination settles the question.
8. For any new pericardial effusion in a patient with known malignancy, actively consider cardiac metastatic involvement as a cause rather than a benign explanation by default.

Clinical Importance

Cardiac tumors reward precision over pattern-matching from general experience, simply because most clinicians will encounter each specific type only a handful of times across an entire career. The distribution percentages on this page — myxoma’s atrial-site breakdown, fibroelastoma’s valve-by-valve frequency, the routes metastatic disease actually travels — exist because they’re genuinely diagnostic: the right atrium raises sarcoma and lymphoma together, not one or the other, and the clinical urgency of telling them apart is precisely why echocardiography’s role here is to narrow the question intelligently and hand it to pathology, not to answer it alone.